8-K: Exagen Reports Record 2025 Revenue, Strong Cash Position

Exagen Inc. announced preliminary unaudited financial results for 2025, reporting record full-year revenue and a significant increase in year-end cash.

Summary

• Exagen Inc. reported preliminary unaudited financial results for the three months and year ended December 31, 2025.
• Total revenue for the full year 2025 is estimated between $66 million and $67 million, representing a year-over-year growth of 19% to 20%.
• Fourth quarter 2025 revenue is estimated between $16 million and $17 million, with year-over-year growth of 17% to 24%.
• AVISE CTD test volume for the full year 2025 reached 136,000 to 137,000, an 11% increase over 2024.
• The AVISE CTD trailing 12-month (TTM) average selling price (ASP) expanded to $441 to $445, an increase of at least $30 compared to 2024.
• Year-end cash and cash equivalents stood at $32 million, a $10 million increase over 2024.

Sentiment

Score: 8

Explanation: The sentiment is highly positive, driven by record revenue, strong year-over-year growth in both revenue and test volume, significant ASP expansion, and a substantial increase in cash reserves. Management's comments reflect confidence in execution and future strategy, despite minor ASP headwinds.

Positives

• Achieved record full year 2025 revenue, increasing at least 19% over 2024.
• Expanded AVISE CTD trailing 12-month (TTM) ASP by at least $30 compared to 2024.
• Experienced AVISE CTD test volume growth of at least 13,000, an 11% increase over 2024.
• Increased year-end cash and cash equivalents to $32 million, a $10 million increase over 2024.
• Delivered significant topline growth driven by both volume and ASP expansion.
• Strengthened scientific and commercial teams.
• Launched the first enhancements to the AVISE platform in several years, with more planned.

Negatives

• Experienced unexpected ASP headwinds in the second half of 2025, despite overall ASP expansion.
• The financial results are preliminary and unaudited, subject to change upon completion of financial closing procedures and audit.

Risks

• Delays in reimbursement and coverage decisions from Medicare and third-party payors.
• Delays in interactions with regulatory authorities.
• Delays in ongoing and planned clinical trials involving its tests.
• Commercial success depends on attaining and maintaining significant market acceptance of testing products among rheumatologists, patients, and third-party payors.
• Ability to successfully execute on business strategies.
• Third-party payors not providing coverage and adequate reimbursement for testing products.
• Ability to obtain and maintain intellectual property protection for testing products.
• Regulatory developments affecting the business.

Future Outlook

The company plans to continue investing in innovation and advancing its strategy to change the standard of care in autoimmune disease, while pursuing the goal of operating a profitable company. Additional enhancements to the AVISE platform are anticipated.

Management Comments

• "I am pleased to report the completion of another strong year for Exagen in which we've continued to make substantial progress in building a great company; a testament to continued execution across our commercial, scientific, and operational teams."
• "Based upon our preliminary results, we delivered significant topline growth, driven by both volume and ASP expansion, despite unexpected ASP headwinds in the second half of the year."
• "We also strengthened our scientific and commercial teams and subsequently launched our first enhancements to the AVISE platform in several years, with more on the horizon."
• "Our strong cash position and disciplined approach provide the flexibility to continue to invest in innovation and advance our strategy to change the standard of care in autoimmune disease while pursuing our goal of operating a profitable company."

Industry Context

Exagen Inc. operates as a leading provider of autoimmune diagnostics, focusing on transforming care for patients with chronic and debilitating autoimmune conditions. Its flagship product, AVISE CTD, is designed to improve the diagnosis of complex autoimmune conditions like lupus, rheumatoid arthritis, and Sjogren's syndrome. The company's efforts in innovation and test platform enhancements align with the broader trend of advancing precision diagnostics in specialized medical fields.

Comparison to Industry Standards

• The filing states that the preliminary financial results are 'in line with prior financial guidance,' indicating performance met internal expectations. However, no specific comparable companies, industry benchmarks, or project results are provided within the filing to assess performance against global or direct competitors.

Stakeholder Impact

• Shareholders: Positive preliminary financial results, including record revenue and increased cash, suggest strong operational performance and potential for future value creation.
• Customers (Clinicians/Patients): Continued investment in innovation and enhancements to the AVISE platform aim to improve diagnostic accuracy and patient outcomes in autoimmune disease management.
• Employees: The strengthening of scientific and commercial teams indicates ongoing investment in human capital and operational capabilities.

Next Steps

• Complete financial closing procedures and audit for the full year ended December 31, 2025.
• Release audited financial statements prepared in accordance with U.S. GAAP for the year ended December 31, 2025.
• Continue to invest in innovation and advance the strategy to change the standard of care in autoimmune disease.
• Introduce additional enhancements to the AVISE platform.

Key Dates

Recommendation

The preliminary results indicate robust financial health and operational execution, with record revenue, significant year-over-year growth, and a strong cash position. The expansion of AVISE CTD volume and average selling price, coupled with management's commitment to innovation and strategic advancement in autoimmune diagnostics, suggests a positive trajectory. While the results are unaudited, the 'in line with guidance' statement provides confidence. These factors make Exagen an attractive investment for growth-oriented portfolios.

Keywords

autoimmune diagnostics, Exagen, XGN, AVISE CTD, financial results, revenue growth, cash position, rheumatology, lupus, rheumatoid arthritis, Sjogren's syndrome